MannKind's (NASDAQ: MNKD )
long and arduous path to FDA approval has finally reached a happy
ending, with the company announcing late on Friday that the agency had
approved Afrezza, the company's inhaled insulin product. Approval is a
major event for MannKind, but the company still needs a commercial
partner and the approved label for Afrezza doesn't do the
product/company any particular favors.
Read more here:
MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?
No comments:
Post a Comment